Print
EmailAmgen on Nov. 25 decided to suspend a clinical trial of its experimental cancer drug motesanib because of higher deaths among patients, setting back the company’s efforts to expand in the market for oncology treatments.
The Thousand Oaks-based pharmaceutical company has made a major push in the past seven years to develop treatments for cancer. It now has eight oncology medicines in late-stage clinical trials needed to gain U.S. regulatory approval, with many more therapies in earlier-stage studies, Bloomberg News reported.
Are you a subscriber? If not, sign up today and get four free issues of the Pacific Coast Business Times!
